Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
07:00am, Thursday, 12'th Feb 2026
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activ
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
04:20am, Wednesday, 11'th Feb 2026
Shares of Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $15.49 and traded as low
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?
04:52am, Friday, 16'th Jan 2026
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $16.63 and traded as low as
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
11:15am, Monday, 29'th Dec 2025
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened
04:14am, Friday, 05'th Dec 2025
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $18.13 and traded a
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
07:00am, Monday, 24'th Nov 2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside ch
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
02:11pm, Wednesday, 05'th Nov 2025
Seres Therapeutics, Inc. ( MCRB ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Carlo Tanzi Marella Thorell - Co-CEO, Co-President & CFO Matthew Henn - Executive VP & Chief S
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Wednesday, 05'th Nov 2025
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transpl
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
07:00am, Thursday, 30'th Oct 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and l
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
07:00am, Wednesday, 29'th Oct 2025
Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections Liquid formulati
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem
More companies adopt co-CEO structure
12:10pm, Monday, 22'nd Sep 2025
Enterprise software maker Oracle on Monday named insiders Clay Magouyrk and Mike Sicilia as co-CEOs, replacing Safra Catz, who was named vice chair of the board after 11 years at the helm.
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
01:01pm, Tuesday, 09'th Sep 2025
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
